Helicase-inactivating BRIP1 mutation yields Fanconi anemia with microcephaly and other congenital abnormalities

Fanconi anemia is a genetically and phenotypically heterogeneous disorder characterized by congenital anomalies, bone marrow failure, cancer, and sensitivity of chromosomes to DNA cross-linking agents. One of the 22 genes responsible for Fanconi anemia is BRIP1, in which biallelic truncating mutations lead to Fanconi anemia group J and monoallelic truncating mutations predispose to certain cancers. However, of the more than 1000 reported missense mutations in BRIP1, very few have been functionally characterized. We evaluated the functional consequence of BRIP1 p.R848H (c.2543G > A), which was homozygous in two cousins with low birth weight, microcephaly, upper limb abnormalities, and imperforate anus and for whom chromosome breakage analysis of patient cells revealed increased mitomycin C sensitivity. BRIP1 p.R848H alters a highly conserved residue in the catalytic DNA helicase domain. We show that BRIP1 p.R848H leads to a defect in helicase activity. Heterozygosity at this missense has been reported in multiple cancer patients but, in the absence of functional studies, classified as of unknown significance. Our results support that this mutation is pathogenic for Fanconi anemia in homozygotes and for increased cancer susceptibility in heterozygous carriers.

[1]  J. Ivanovich,et al.  Rare BRIP1 missense alleles confer risk for ovarian and breast cancer. , 2019, Cancer research.

[2]  A. Toren,et al.  Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population , 2019, Haematologica.

[3]  N. Giri,et al.  Genotype-phenotype associations in Fanconi anemia: A literature review. , 2019, Blood reviews.

[4]  Y. Kamatani,et al.  Germline Pathogenic Variants in 7636 Japanese Patients With Prostate Cancer and 12 366 Controls , 2019, Journal of the National Cancer Institute.

[5]  A. D’Andrea,et al.  The Fanconi Anemia Pathway in Cancer. , 2019, Annual review of cancer biology.

[6]  Matt A. King,et al.  Essential Role of BRCA2 in Ovarian Development and Function , 2018, The New England journal of medicine.

[7]  Raymond M. Moore,et al.  Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing , 2018, Journal of the National Cancer Institute.

[8]  K. Shin‐ya,et al.  A minimal threshold of FANCJ helicase activity is required for its response to replication stress or double-strand break repair , 2018, Nucleic acids research.

[9]  T. Walsh,et al.  Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1 , 2018, Proceedings of the National Academy of Sciences.

[10]  J. Ramser,et al.  BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer , 2018, Breast Cancer Research.

[11]  Robert Huether,et al.  Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer , 2017, JAMA oncology.

[12]  A. Shimamura,et al.  Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia. , 2017, Blood reviews.

[13]  Trevor Hastie,et al.  REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. , 2016, American journal of human genetics.

[14]  kConFab investigators,et al.  No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing , 2016 .

[15]  Tom Walsh,et al.  Inherited Mutations in Women With Ovarian Carcinoma. , 2016, JAMA oncology.

[16]  A. Alsultan,et al.  Clinical characteristics and genetic subtypes of Fanconi anemia in Saudi patients. , 2016, Cancer genetics.

[17]  S. Cross,et al.  No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing , 2016, Journal of Medical Genetics.

[18]  J. Lee,et al.  Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[19]  Lara E Sucheston-Campbell,et al.  Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. , 2015, Journal of the National Cancer Institute.

[20]  D. Bercovich,et al.  Minichromosome maintenance complex component 8 (MCM8) gene mutations result in primary gonadal failure , 2015, Journal of Medical Genetics.

[21]  Martin Kircher,et al.  Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. , 2015, Cancer discovery.

[22]  B. Alter.  Fanconi anemia and the development of leukemia. , 2014, Best practice & research. Clinical haematology.

[23]  Manhong Guo,et al.  Insight into the Roles of Helicase Motif Ia by Characterizing Fanconi Anemia Group J Protein (FANCJ) Patient Mutations* , 2014, The Journal of Biological Chemistry.

[24]  F. Alkuraya,et al.  Genomic analysis of primordial dwarfism reveals novel disease genes , 2014, Genome research.

[25]  E. Ostrander,et al.  Massively parallel sequencing, aCGH, and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia. , 2013, Blood.

[26]  F. Couch,et al.  Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. , 2013, Cancer discovery.

[27]  Molly C. Kottemann,et al.  Fanconi anaemia and the repair of Watson and Crick DNA crosslinks , 2013, Nature.

[28]  S. Spunt,et al.  The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations , 2012, Pediatric blood & cancer.

[29]  A. Gylfason,et al.  Mutations in BRIP1 confer high risk of ovarian cancer , 2011, Nature Genetics.

[30]  A. Figuera,et al.  Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. , 2011, Blood.

[31]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[32]  B. Alter,et al.  Pathophysiology and management of inherited bone marrow failure syndromes. , 2010, Blood reviews.

[33]  K. Shin‐ya,et al.  Fanconi anemia group J mutation abolishes its DNA repair function by uncoupling DNA translocation from helicase activity or disruption of protein-DNA complexes. , 2010, Blood.

[34]  D. G. Gibson,et al.  Enzymatic assembly of DNA molecules up to several hundred kilobases , 2009, Nature Methods.

[35]  B. Sobhian,et al.  A Novel Breast Cancer–Associated BRIP1 (FANCJ/BACH1) Germ-line Mutation Impairs Protein Stability and Function , 2008, Clinical Cancer Research.

[36]  S. Cantor,et al.  The FANCJ/MutLα interaction is required for correction of the cross‐link response in FA‐J cells , 2007, The EMBO journal.

[37]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[38]  M. F. White,et al.  The DNA repair helicases XPD and FancJ have essential iron-sulfur domains. , 2006, Molecular cell.

[39]  P. Rosenberg,et al.  Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2 , 2006, Journal of Medical Genetics.

[40]  S. Cantor,et al.  BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. , 2005, Cancer cell.

[41]  C. Mathew,et al.  The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J , 2005, Nature Genetics.

[42]  J. Ott,et al.  The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia , 2005, Nature Genetics.

[43]  S. Cantor,et al.  Analysis of the DNA Substrate Specificity of the Human BACH1 Helicase Associated with Breast Cancer* , 2005, Journal of Biological Chemistry.

[44]  L. Loeb,et al.  The Enzymatic Activities of the Werner Syndrome Protein Are Disabled by the Amino Acid Polymorphism R834C* , 2004, Journal of Biological Chemistry.

[45]  A. D’Andrea,et al.  Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. , 2004, Blood.

[46]  C. Mathew,et al.  Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. , 2004, Blood.

[47]  D. Livingston,et al.  The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[48]  D. Sgroi,et al.  BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function , 2001, Cell.

[49]  C. Lewis,et al.  Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group. , 2000, Blood.

[50]  R. Monnat,et al.  WRN helicase expression in Werner syndrome cell lines. , 2000, Nucleic acids research.

[51]  T. Ludwig,et al.  Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. , 1997, Genes & development.

[52]  J. Rossant,et al.  The Tumor Suppressor Gene Brca1 Is Required for Embryonic Cellular Proliferation in the Mouse , 1996, Cell.

[53]  B. Koller,et al.  Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities , 1996, Nature Genetics.

[54]  K. Kyriacou,et al.  Fanconi anemia-D1 due to homozygosity for the BRCA2 gene Cypriot founder mutation: A case report. , 2016, Oncology letters.

[55]  P. Rosenberg,et al.  Clinical and molecular features associated with biallelic mutations in FANCD 1 / BRCA 2 , 2006 .

[56]  S. Enerbäck,et al.  The BRCA 1-associated protein BACH 1 is a DNA helicase targeted by clinically relevant inactivating mutations , 2004 .